RNA sequencing analysis indicated significantly higher PD-L1 expression at the mRNA and protein levels in patients with HER2-amplified LUAD than in those with breast invasive carcinoma (BRCA) and stomach adenocarcinoma (STAD). This evidence concerns the gene ERBB2 and gastric adenocarcinoma.